Presentations ESC 2022 Poster: Nomination of VERVE-201 ANGPTL3 Product Candidate ESC 2022 Investor Presentation: Nomination of VERVE-201 ANGPTL3 Product Candidate July 2022 Investor Presentation ASGCT 2022 presentation ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene TIDES 2022: In Vivo CRISPR Base Editing to Treat ASCVD Keystone Symposia 2022: Off-target Analyses ACC 2022: Sequential in vivo CRISPR base editing of the PCSK9 and ANGPTL3 genes in NHPs Verve Therapeutics Presentation at the 40th Annual J.P. Morgan Healthcare Conference In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia Pagination Current page 1 Page 2 Next page next › Last page last »
ESC 2022 Poster: Nomination of VERVE-201 ANGPTL3 Product Candidate ESC 2022 Investor Presentation: Nomination of VERVE-201 ANGPTL3 Product Candidate July 2022 Investor Presentation ASGCT 2022 presentation ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene TIDES 2022: In Vivo CRISPR Base Editing to Treat ASCVD Keystone Symposia 2022: Off-target Analyses ACC 2022: Sequential in vivo CRISPR base editing of the PCSK9 and ANGPTL3 genes in NHPs Verve Therapeutics Presentation at the 40th Annual J.P. Morgan Healthcare Conference In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia Pagination Current page 1 Page 2 Next page next › Last page last »
ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene
In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia